68.52 -0.53 (-0.77%)
After hours: 4:11PM EST
|Bid||69.08 x 1000|
|Ask||69.16 x 900|
|Day's Range||66.38 - 69.32|
|52 Week Range||41.19 - 155.75|
|Beta (3Y Monthly)||1.49|
|PE Ratio (TTM)||47.92|
|Earnings Date||Nov. 5, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||68.70|
Kaskela Law LLC has commenced an investigation of Inogen, Inc. (“Inogen” or the “Company”) (INGN) on behalf of the Company’s stockholders. Stockholders who purchased shares of Inogen’s common stock before November 8, 2017 are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq.) at (888) 715 – 1740, or via email at firstname.lastname@example.org, to discuss this investigation and their legal rights and options. Additional information about this investigation may also be requested at http://kaskelalaw.com/case/inogen/.
Inogen, Inc. , a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that the Company’s management will be participating in the Stifel 2019 Healthcare Conference in New York.
Inogen (INGN) delivered earnings and revenue surprises of 34.78% and 0.42%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Inogen (INGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Inogen, Inc. , a medical technology company offering innovative respiratory products for use in the homecare setting, announced that it will release third quarter 2019 financial results after market close on Tuesday, November 5, 2019.
Shareholder rights law firm Robbins Arroyo LLP reminds investors that shareholders of Inogen filed a class action complaint against the company for alleged violations of the Securities Exchange Act of 1934 between November 8, 2017 and February 26, 2019.
Bragar Eagel & Squire, P.C. is investigating potential claims against certain officers and directors of Inogen Inc. (INGN) on behalf of long-term stockholders. Our investigating follows a class action complaint that was filed against Inogen on March 6, 2019. The complaint alleges that during the class period, defendants made false and misleading statements and/or failed to disclose adverse information regarding Inogen’s business metrics and financial prospects.
Inogen, Inc. (NASDAQ:INGN) shareholders might be concerned after seeing the share price drop 24% in the last quarter...
These two former Wall Street darlings have taken a beating after posting disappointing results for the second time in a row. Are these stocks bad-news buys, or could there be more trouble ahead?
Inogen, Inc. (NASDAQ:INGN), which is in the medical equipment business, and is based in United States, received a lot...